Reviewing Nabriva Therapeutics plc (NBRV)’s and Voyager Therapeutics Inc. (NASDAQ:VYGR)’s results

Since Nabriva Therapeutics plc (NASDAQ:NBRV) and Voyager Therapeutics Inc. (NASDAQ:VYGR) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation of both companies.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nabriva Therapeutics plc 3.81M 37.92 121.66M -2.16 0.00
Voyager Therapeutics Inc. 11.87M 75.19 95.53M -2.94 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Nabriva Therapeutics plc and Voyager Therapeutics Inc.


Table 2 demonstrates the net margins, return on assets and return on equity of Nabriva Therapeutics plc and Voyager Therapeutics Inc.

Net Margins Return on Equity Return on Assets
Nabriva Therapeutics plc -3,193.18% 0% 0%
Voyager Therapeutics Inc. -804.80% -129.7% -38.2%

Volatility & Risk

Nabriva Therapeutics plc has a 2.49 beta, while its volatility is 149.00%, thus making it more volatile than Standard & Poor’s 500. Voyager Therapeutics Inc.’s 168.00% more volatile than Standard & Poor’s 500 which is a result of the 2.68 beta.


The current Quick Ratio of Nabriva Therapeutics plc is 5.6 while its Current Ratio is 5.6. Meanwhile, Voyager Therapeutics Inc. has a Current Ratio of 6.2 while its Quick Ratio is 6.2. Voyager Therapeutics Inc. is better positioned to pay off its short-term and long-term debts than Nabriva Therapeutics plc.

Analyst Ratings

Nabriva Therapeutics plc and Voyager Therapeutics Inc. Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Nabriva Therapeutics plc 0 0 0 0.00
Voyager Therapeutics Inc. 0 0 1 3.00

Competitively the consensus price target of Voyager Therapeutics Inc. is $27, which is potential 11.39% upside.

Institutional & Insider Ownership

The shares of both Nabriva Therapeutics plc and Voyager Therapeutics Inc. are owned by institutional investors at 53% and 82.3% respectively. Insiders owned roughly 0.1% of Nabriva Therapeutics plc’s shares. On the other hand, insiders owned about 12.3% of Voyager Therapeutics Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Nabriva Therapeutics plc 19.57% 5.36% 35.47% 27.31% -44.78% 88.36%
Voyager Therapeutics Inc. -3.27% 18.51% 122.44% 92.29% 22.05% 152.02%

For the past year Nabriva Therapeutics plc was less bullish than Voyager Therapeutics Inc.


Voyager Therapeutics Inc. beats on 8 of the 11 factors Nabriva Therapeutics plc.

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of novel antibiotics to treat serious bacterial infections with a focus on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, a novel semi-synthetic pleuromutilin antibiotic for systemic administration in humans. The companyÂ’s product, lefamulin is being studied in two registrational Phase 3 clinical trials in patients with moderate to severe community-acquired bacterial pneumonia. It is also developing lefamulin that has completed Phase 2 clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as in preclinical studies for antibacterial activity against various gram-positive bacteria, gram-negative bacteria, and atypical bacteria, including multi-drug resistant strains. In addition, the company is developing BC-7013, a topical pleuromutilin product candidate, which has completed a Phase 1 clinical trial for the treatment of various gram-positive infections, including uncomplicated skin and skin structure infections. Nabriva Therapeutics plc was founded in 2006 and is based in Dublin, Ireland.

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. The companyÂ’s lead clinical candidate is the VY-AADC01, which is in Phase Ib clinical trial for the treatment of advanced Parkinson's disease. Its preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis; VY-HTT01 for HuntingtonÂ’s disease; VY-FXN01 for Friedreich's ataxia; VY-TAU01, AlzheimerÂ’s disease; and VY-NAV01 for severe chronic pain. The company has strategic collaboration agreements with Genzyme Corporation and the University of Massachusetts. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.